Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis

NCT05194540 is registered in ClinicalTrials.gov with LEO Pharma as lead sponsor.

NCT NCT05194540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05194540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Subjects With Moderate-to-severe Atopic Dermatitis
Lead sponsor
LEO Pharma
Phase
Phase 3
Overall status
Completed
Start date
January 13, 2022
Completion date
June 21, 2023
Enrollment
136 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis